AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
Collegium Pharmaceutical
COLL
SilverCrest Metals
SILV
Enerpac Tool
EPAC
Halozyme Therapeutics
HALO
US Stock MarketDetailed Quotes
CMMB Chemomab Therapeutics
- 1.620
- -0.010-0.61%
Close Feb 27 16:00 ET
- 1.600
- -0.020-1.23%
Post 18:36 ET
30.55MMarket Cap-1.72P/E (TTM)
1.703High1.620Low101.87KVolume1.620Open1.630Pre Close168.85KTurnover0.86%Turnover RatioLossP/E (Static)18.86MShares2.55052wk High1.87P/B19.15MFloat Cap0.57952wk Low--Dividend TTM11.82MShs Float184.000Historical High--Div YieldTTM5.10%Amplitude0.420Historical Low1.657Avg Price1Lot Size
Chemomab Therapeutics News
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $7
Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Blueprint Medicines (BPMC)
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $11
Market-Moving News for February 19th
Express News | Chemomab Therapeutics Shares Are Trading Higher After the Company Announced the Completion of Its End-of-phase 2 FDA Meeting and Alignment on a Single Phase 3 Registration Study for Nebokitug
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns With FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
Chemomab Therapeutics Aligns Leadership Incentives With Shareholders
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Cuts Target Price to $11
Chemomab Therapeutics Analyst Ratings
Express News | Chemomab Therapeutics Ltd. : Oppenheimer Cuts Target Price to $11 From $13
Chemomab Therapeutics Sees Cash Runway Through Beginning of 2026
Express News | Chemomab Therapeutics Q3 2024 GAAP EPS $(0.20) Misses $(0.01) Estimate
Chemomab Therapeutics 3Q EPS 1c >CMMB
Earnings Scheduled For November 14, 2024
Earnings Preview: CMMB to Report Financial Results Pre-market on November 14
Express News | Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Express News | Chemomab Therapeutics Announces Late-Breaking Oral Presentation of Cm-101 Phase 2 Results in Primary Sclerosing Cholangitis at Aasld the Liver Meeting® 2024